The Role of Microbiome in Recurrent Obesity

Obesity Clinical Trial

Official title: The Role of Microbiome in Recurrent Obesity

Status Not yet recruiting

Clinical Trial Summary

This past century witnessed a significant increase in the prevalence of obesity. successful maintenance of weight loss is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping the low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. For instance, fecal microbiota transplant (FMT) or fecal bacteriotherapy, is the process of transferring stool from a healthy donor to another. Although numerous individual microbes have been identified as related to obesity, multiple studies suggest that loss of microbial diversity has a stronger impact on the development of metabolic dysfunction, this diversity may be restored by FMT. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered FMT from a lean donor, post weight loss might be an effective intervention to prevent weight regain.

Clinical Trial Description

This is a placebo-controlled, double blinded interventional study evaluating high intensity oral fecal microbiota transplantation from lean healthy donors to prevent weight regain after a successful weight loss intervention. Volunteers will be recruited in the following ways: e-mail, and social media. Volunteers wishing to participate will be asked to complete a questionnaire regarding the aforementioned inclusion and exclusion criteria. Volunteers who qualify for the study will be invited to an introductory meeting at the Weizmann Institute of Science. The details of the experiment and potential risks or discomforts involved in it will be presented, after which the volunteers will sign informed consent forms. Volunteers will start the study and become active participants for a maximal duration of two years, depending on the weight loss process

The study will comprise of four parts:

1. Baseline - one week of profiling and screening.

2. Nutritional intervention - weight loss intervention which will be based on Mediterranean hypocaloric diet restriction. Meetings will occur every two weeks starting from the second week of the study.

3. FMT/ Placebo intervention - 5 weekly cycles of high intensity lean donor FMT/placebo will be administered starting after reaching a weight loss of 5 to 10% of total body weight. Each cycle will consist of 10 capsules administered on two consecutive days (total 100 capsules)

4. Follow-up meetings - total follow up of one year after FMT cycles. Meetings will occur every month for the first 3 months of the study, and every 3 months, Afterwards. ;

Related Conditions & MeSH terms

• FMT
• Obesity
• Weight Loss

• NCT number: NCT04697550
• Study type: Interventional
• Source: Weizmann Institute of Science
• Contact: aurelie Bukimer mimran
• Phone: +97289529089
• Email: aurelie.bukimer@weizmann.ac.il
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2022
• Completion date: September 1, 2025